Travaux scientifiques

Doç. Dr. Yaşa Gül Mutlu

21 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Balik Aydin B, Mutlu YG, Sevindik OG. Persistent Polyclonal B-Cell Lymphocytosis with Binucleated Lymphocytes. Turk J Haematol. 2021;38(2):173-4.

    Source : page de profil sur florence.com.tr

  2. Civriz Bozdag S, Cengiz Seval G, Yonal Hindilerden I, Hindilerden F, Andic N, Baydar M, …. Mutlu YG ,…et al. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turk J Haematol. 2022;39(1):43- 54.

    Source : page de profil sur florence.com.tr

  3. Sevindik OG, Mergen M, Mergen S, Mutlu YG, Aydin BB, Serin I. To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission. Ann Hematol. 2022;101(11):2545-7.

    Source : page de profil sur florence.com.tr

  4. Sevindik OG, Mutlu YG, Aydin BB, Serin I. First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS). Hemasphere. 2022;6(7):e728.

    Source : page de profil sur florence.com.tr

  5. Yigit Kaya S, Bektas S, Askin AE, Balik Aydin B, Mutlu YG, Sevindik OG. Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient. Ann Hematol. 2023;102(6):1599-600.

    Source : page de profil sur florence.com.tr

  6. Mutlu YG, Aydin BB, Erdogan C, Kizilaslan D, Bekoz HS, Gemici A, et al. Prognostic Factors and Intensive Care Outcome in Post-Transplant Phase of Hematopoietic Stem Cell Transplantation: Intensive Care Outcome in Hematopoietic Stem Cell Transplantation. Indian J Hematol Blood Transfus. 2023;39(2):167-72.

    Source : page de profil sur florence.com.tr

  7. Mutlu YG, Balik Aydin B, Ayaz A, Seca F, Sevindik OG. Mutation profile of the patients diagnosed with myeloid neoplasia tested with next generation sequencing andclinical implications. Annals of Medical Research. 2022; 29(4), 406-411.

    Source : page de profil sur florence.com.tr

  8. Sadri S. , Yönal Hindilerden İ. , Mutlu YG. , Tiryaki T. O. , Gemici A. İ. , Bekoz H. S. , Gökmen Sevindik Ö. , Hindilerden F. , Kalayoğlu beşışık S. , Nalçacı M. , Sargın D. Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers. Eur Res J. 2023; 1-12.

    Source : page de profil sur florence.com.tr

  9. Mutlu YG, Aydin BB, Cakir A, Canoz O, Erol C, Sevindik OG.Should core needle lymph node biopsy be a relevant alternative to surgical excisional biopsy in diagnostic work up of lymphomas? 2023, Eurasian J Med.

    Source : page de profil sur florence.com.tr

  10. Erol VB, Mutlu YG, Aydin BB, Mert A, Sevindik OG. Intravascular B cell lymphoma with generalized telangiectasias: a rare entity. 2023, J Dtsch Dermatol Ges.

    Source : page de profil sur florence.com.tr

  11. Mutlu YG, Sevcik J, Kiss JE, Lister J, Moore LR, Donnenberg AD. Predicting the CD34 content of mobilized peripheral blood leukapheresis products: single institution experience over 20 years. Cytotherapy. 2023.

    Source : page de profil sur florence.com.tr

  12. Mutlu YG, Yigit Kaya S, Maral S, Melek E, Baslar Z, Kaynar L, et al. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. Front Immunol. 2023;14:1276295.

    Source : page de profil sur florence.com.tr

  13. Serin I, Sevindik OG, Balik Aydin B, Melek E, Mutlu YG, Bilgen H, et al. Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics? Transfus Apher Sci. 2023;62(6):103809.

    Source : page de profil sur florence.com.tr

  14. Askin AE, Bektas S, Serin I, Mutlu YG, Aydin BB, Sevindik OG. Germline CEBPA Mutation as a Rare Cause of Chronic Neutropenia. Indian J Hematol Blood Transfus. 2024;40(3):527-30.

    Source : page de profil sur florence.com.tr

  15. Sevindik OG, Mutlu YG, Demirkan F. The Contributions of Turkish Hematology to the Global Literature: A Comparative Analysis. Turk J Haematol. 2025;42(3):246-9. doi:10.4274/tjh.galenos.2025.2025.0029.

    Source : page de profil sur florence.com.tr

  16. Yigit Kaya S, Kaynar L, Mutlu YG, Yildirim M, Serin I, Avci DN et al. Myth or reality: Graft versus host disease after autologous hematopoietic cell transplantation, a multicentre experience. Transpl Immunol. 2025;93:102286. doi:10.1016/j.trim.2025.102286

    Source : page de profil sur florence.com.tr

  17. Yigit Kaya S, Melek E, Mutlu YG, Bekoz HS, Maral S, Kaynar L et al. When high dose methotrexate stops working, a successful bridge to transplant with TEDDI-R in a case of secondary CNS lymphoma. Ann Hematol. 2025;104(3):2079-80. doi:10.1007/s00277-025-06285-2.

    Source : page de profil sur florence.com.tr

  18. Yigit Kaya S, Mutlu YG, Malkan UY, Mehtap O, Keklik Karadag F, Korkmaz G et al. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience. Leuk Res. 2024;140:107495. doi:10.1016/j.leukres.2024.107495

    Source : page de profil sur florence.com.tr

  19. Yigit Kaya S, Mutlu YG, Yucel OK, Nizam Ozen I, Atas U, Melek E et al. Original vs. Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients. Indian J Hematol Blood Transfus. 2025;41(1):38-42. doi:10.1007/s12288-024-01841-8.

    Source : page de profil sur florence.com.tr

  20. Mutlu YG, Emre Unsal S, Gulec B, Serin I, Arslan Davulcu E, Sonmez GM et al. The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History. Clin Lymphoma Myeloma Leuk. 2025. doi:10.1016/j.clml.2025.10.006.

    Source : page de profil sur florence.com.tr

  21. Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM et al. Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients. Am J Hematol. 2026;101(1):89-96. doi:10.1002/ajh.70142.

    Source : page de profil sur florence.com.tr